The table below summarizes the key differences between what happened to these three major vendors: Understanding what happened to Amino Asylum, Paradigm Peptides, and Peptide Sciences as separate events with separate causes is essential for evaluating which risk factors to watch for in any supplier
If someone is using BPC-157, TB-500, or similar peptides for human treatment outside of a properly authorized clinical trial , there is no FDA-recognized lawful prescription pathway for that use
The most common side effects are mild and may include pain or redness at the injection site, mild diarrhea, nausea, or a feeling of swelling all over the body
The form you receive them ina chalky, freeze-dried puck at the bottom of a vialis called a lyophilized state
Questions I would like both companies to answer Before treating any format as a demonstrated bioavailability leader, I would ask for the following
That's when the worrying starts